Luxdegalutamide

Luxdegalutamide (ARV-766) is an orally active protein hydrolysis targeted chimeric (PROTAC) targeting androgen receptor (AR), which can degrade AR resistance related mutants, including T878/H875/L702 mutants. Luxdegalutamide has anti-tumor activity and can be used in the study of castration resistant prostate cancer[1][2].

Product Specifications

CAS Number

[2750830-09-0]

Product Name Alternative

ARV-766

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Androgen Receptor; PROTACs

Type

Reference compound

Related Pathways

PROTAC; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/luxdegalutamide.html

Purity

98.99

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)([C@@H](C1(C)C)NC(C2=CC=C(N3CCC(CC3)CN4CCN(C5=CC(F)=C(C=C5)C(N[C@@H]6C(NC(CC6)=O)=O)=O)CC4)C=C2)=O)[C@@H]1OC7=CC(OC)=C(C=C7)C#N

Molecular Formula

C45H54FN7O6

Molecular Weight

807.95

Precautions

H302, H315, H319

References & Citations

[1]Snyder L, et al. In vitro evaluation of PROTAC® degrader ARV-766 for cytochrome P450-and transporter-mediated drug-drug interaction[J]. Drug Metabolism and Pharmacokinetics, 2024, 55: 100881.|[2]Snyder L, et al. Abstract ND03: Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer[J]. Cancer Research, 2023, 83 (7_Supplement) : ND03-ND03.